We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Congenital Anemia Patients Should Be Tested for Pearson Syndrome

By LabMedica International staff writers
Posted on 19 Dec 2013
Print article
Image: Bone marrow smear from a patient with Diamond Blackfan Anemia (Photo courtesy of American Society of Hematology).
Image: Bone marrow smear from a patient with Diamond Blackfan Anemia (Photo courtesy of American Society of Hematology).
Some infants diagnosed with and treated for a bone marrow failure disorder, called Diamond Blackfan Anemia, may actually be affected by a very rare anemia syndrome that has a different disease course and treatment.

Diagnosing the rare Pearson Marrow Pancreas syndrome (PS) is not simple, but a specific laboratory test can spot a characteristic abnormality in the infant's DNA that carries blueprints for making proteins in the cells' energy-producing mitochondria.

Scientists at the Dana-Farber Cancer Institute (Boston, MA, USA) genetically analyzed DNA from 175 patients believed to have Diamond Blackfan Anemia, and identified 8 that showed hallmarks of PS. The two disorders are caused by genetic abnormalities that impair production of blood cells by the bone marrow, causing severe anemia usually diagnosed in the first year of life.

Diamond Blackfan Anemia is typically inherited from parents in an autosomal dominant fashion, with only one parent carrying the abnormal gene, so each pregnancy carries a 50% risk of resulting in an affected child. Diamond Blackfan Anemia affects approximately 1 in 100,000 infants and can vary widely in its severity. About 50% of patients have physical abnormalities affecting different parts of the body.

Infants with PS also have anemia and growth defects. They are deficient in pancreatic function and can have muscle and neurologic impairments. It is not always diagnosed in infancy, because the anemia may not be severe and can even improve without treatment. That is because the patient's cells carry a mixture of normal and mutant mitochondrial DNA. Over time, the proportion of mutant mitochondrial DNA in the blood cells may lessen and the anemia becomes less severe.

Suneet Agarwal, MD, PhD, a pediatric hematologist, said, “Some patients with Diamond Blackfan will respond to steroids, but there's no reason to give steroids to someone with Pearson Syndrome and they could make things worse. Most patients with Diamond Blackfan Anemia require blood transfusions into adulthood. If you're going to do a transplant in a patient with Diamond Blackfan, outcomes are better if you do it early. Because patients with Pearson Syndrome can get over their blood defect as young children, and because bone marrow transplantation does not cure the other problems in their bodies, the decision to proceed with transplant is more difficult.” The study was presented at the 55th annual meeting of the American Society of Hematology held December 7–10, 2103, in New Orleans, (LA, USA).

Related Links:

Dana-Farber Cancer Institute


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.